Key Findings From Recent Trials

• INN (International Nonproprietary Name): Mefenamic acid
• Brand Names Available In United Kingdom: not specified
• ATC Code: M01AG01
• Forms & Dosages: Capsules 250 mg; Tablets 250 mg and 500 mg; Oral suspension 50 mg/5 ml and 100 mg/5 ml (Asia)
• Manufacturers In United Kingdom: not specified
• Registration Status In United Kingdom: not specified
• OTC / Rx Classification: Prescription-only (Rx) in most jurisdictions (including USA, EU, Romania)

Major 2022–2025 Studies

Are there new trials that change how clinicians use mefenamic acid?

Recent controlled trials remain limited compared with other non-steroidal anti-inflammatory drugs.

The strongest contemporary evidence continues to support use in primary dysmenorrhoea and short-term acute mild-to-moderate pain.

Small randomised controlled trials and pooled analyses across 2022–2025 report rapid pain relief when single-dose regimens start at 500 mg with 250 mg maintenance every six hours.

Comparative trials versus ibuprofen and naproxen give inconsistent results, with some real-world datasets showing similar analgesia but higher gastrointestinal upset with mefenamic acid.

Main Outcomes

For period pain, early use at the onset of menses gives the best symptom control.

Single 500 mg loading doses followed by 250 mg every six hours commonly produced faster relief than placebo in pooled analyses.

Dysmenorrhoea trials show meaningful pain reduction for a majority of patients when mefenamic acid is taken promptly.

Head-to-head efficacy versus ibuprofen or naproxen varies between studies and populations.

Safety Observations

Pharmacovigilance summaries from 2022–2025 emphasise gastrointestinal adverse events as the commonest issue.

Rare reports of hepatic enzyme elevations have been noted and warrant monitoring in at-risk patients.

Renal impairment increases risk of complications and elderly patients show higher adverse-event rates.

Regulatory reporting confirms mefenamic acid remains prescription-only in most EU states and variable OTC availability in parts of Asia.

MHRA-style guidance in the UK supports conservative short-duration use: up to one week for acute pain and two to three days for dysmenorrhoea.

Evidence gaps include large modern head-to-head randomised trials and long-term cardiovascular safety assessments.

Clinical Mechanism Of Action

Layman’s Explanation

What does mefenamic acid do when you take it for period pain?

Mefenamic acid reduces the production of chemicals called prostaglandins that cause pain and uterine cramping.

That lowers the intensity of cramps and the overall sense of pain during a period or after an injury that produces prostaglandin-driven pain.

Scientific Breakdown

How does the drug act at a molecular level?

COX Inhibition And Prostaglandins

Mefenamic acid is a fenamate NSAID that non-selectively inhibits cyclo-oxygenase enzymes COX-1 and COX-2.

This inhibition decreases levels of prostaglandins such as PGE2 and PGF2α which mediate nociception and uterine contractility.

The reduction in these prostaglandins explains clinical benefit in primary dysmenorrhoea and acute prostaglandin-driven inflammatory pain.

Pharmacokinetics (Practical Points)

Oral formulations are the usual route, with 250 mg capsules widespread and 500 mg tablets sold in some markets.

Onset of analgesia is typically within 30–60 minutes after an oral dose.

Duration of effect usually lasts six to eight hours per dose which supports six-hourly dosing in practice.

Metabolism is hepatic and metabolites are excreted renally, so caution is required in hepatic or renal impairment.

Licensed use is generally for adolescents and adults aged 14 years and over where dosing instructions apply.

Compared with other NSAIDs, fenamates can show a different tolerability profile with somewhat greater reports of dyspepsia in some series.

Scope Of Approved And Off-Label Use

United Kingdom Approvals

Is mefenamic acid an approved treatment for period pain in the UK?

Product information lists mefenamic acid as licensed for short-term relief of acute mild-to-moderate pain and primary dysmenorrhoea.

Typical adult dosing per product information is an initial 500 mg dose followed by 250 mg every six hours as needed.

Treatment duration is usually limited to up to one week for acute pain and two to three days for dysmenorrhoea.

Local formularies in the UK may restrict use in elderly patients or those with renal, hepatic, or bleeding-risk concerns.

Notable Off-Label Trends

Clinicians sometimes prescribe mefenamic acid for musculoskeletal flares or post‑dental pain when other NSAIDs are unsuitable.

Pediatric formulations such as oral suspensions (50 mg/5 ml or 100 mg/5 ml) are marketed in Asia, but use in children under 14 is generally not recommended due to limited safety data.

In UK practice, ibuprofen and naproxen are often preferred because of larger trial datasets and clearer safety margins.

Regulatory status remains prescription-only in the UK and many other jurisdictions.

Dosage Strategy

General Dosing

What dose should a typical adolescent or adult take?

Standard dosing for adults and adolescents aged 14 years and over is a 500 mg initial dose followed by 250 mg every six hours as required.

The maximum duration for short-course use is usually limited to one week for acute pain indications.

For dysmenorrhoea, the same dosing applies but treatment is commonly limited to two to three days per menstrual period.

Condition-Specific Dosing

How do regimens differ by problem?

Acute Mild-To-Moderate Pain

Start with a 500 mg loading dose then 250 mg every six hours PRN.

Avoid continuous use beyond seven days unless supervised by a prescriber.

Primary Dysmenorrhoea

Begin at the first onset of cramps with a 500 mg initial dose followed by 250 mg every six hours.

Regular dosing during the peak pain period gives better control than purely as-needed dosing for many patients.

Special Populations

Children under 14 are generally not recommended to use mefenamic acid in many regions because of limited data.

In elderly patients reduce dose and monitor closely because of increased gastrointestinal and renal risk.

Severe renal or hepatic impairment is a contraindication, and caution is required in mild-to-moderate impairment with specialist advice.

Safety Protocols

Contraindications

Who must not take mefenamic acid?

Absolute contraindications include known hypersensitivity to mefenamic acid, NSAIDs or salicylates.

Any history of NSAID-induced asthma, urticaria, or allergic-type reactions is a contraindication.

Active peptic ulcer, gastrointestinal bleeding, severe renal or hepatic impairment, and peri-operative pain in the setting of CABG surgery are also contraindications.

Adverse Effects

What side effects should patients expect and how common are they?

Gastrointestinal complaints are the most frequent: stomach pain, dyspepsia, heartburn, nausea, and diarrhoea or constipation.

Neurological effects such as headache, dizziness and drowsiness are reported.

Dermatological reactions including mild rash or pruritus occur in some patients.

Less common effects include fluid retention, oedema and transient increases in blood pressure.

Serious but rare events include gastrointestinal bleeding, renal failure and severe hepatic reactions.

Mitigation strategies include using the lowest effective dose for the shortest time and considering a proton-pump inhibitor for patients at high gastrointestinal risk if NSAID therapy cannot be avoided.

Interaction Mapping

Food Interactions

Does food affect mefenamic acid?

Food has minimal effect on analgesic efficacy but taking the tablet with food can reduce stomach upset.

Drug Combinations To Avoid

Which medicines should not be combined with mefenamic acid?

Anticoagulants & Antiplatelets

Combining NSAIDs with warfarin, DOACs or antiplatelet agents increases bleeding risk and should be avoided where possible.

ACE Inhibitors/ARBs/Diuretics

Concurrent use increases the risk of renal impairment due to reduced prostaglandin-mediated renal blood flow.

Monitor renal function and blood pressure if co-prescribing.

Other NSAIDs/Aspirin

Avoid co-administration with other NSAIDs because of additive toxicity.

Low-dose aspirin's cardioprotective effect may be impacted by NSAID use and should be assessed carefully.

Lithium, Methotrexate, Digoxin

NSAIDs can raise plasma lithium and methotrexate levels and affect digoxin clearance; monitoring is required if combinations are unavoidable.

Hepatic Enzyme Interactions

Because the drug is metabolised in the liver, strong hepatic enzyme inducers or inhibitors may alter exposure.

Always check the BNF or SmPC for up-to-date interaction guidance before prescribing.

Patient Experience Analysis

Survey Data

What do patients report about the drug?

Audits and pain-clinic surveys indicate that many women with primary dysmenorrhoea obtain meaningful relief with mefenamic acid when taken early in menses.

Estimates from surveys suggest 60–80% report significant pain reduction when dosing is timely.

Tolerance issues, particularly dyspepsia and nausea, commonly cause patients to switch to ibuprofen or paracetamol.

Forum Trends

What do threads on UK forums say about mefenamic acid?

Patients often report rapid onset of cramp relief and appreciate six-hour dosing intervals.

Common complaints include gastric discomfort and occasional dizziness.

Negative experiences frequently involve inadequate counselling about existing peptic ulcer disease, concurrent anticoagulant use, or renal problems.

Improving patient experience means clear dosing advice, taking with food, limiting duration, and explaining red flags that prompt medical review.

Distribution And Pricing Landscape

Market Overview

Which brands and pack sizes are common?

Ponstan and Ponstel are historical brand names, but many markets now use generics labelled mefenamic acid.

Typical packs contain 250 mg capsules or 250–500 mg tablets depending on market.

Generics are competitively priced but NHS formularies tend to favour ibuprofen and naproxen for cost-effectiveness and clearer safety evidence.

Manufacturers And Supply

Global suppliers include Indian manufacturers such as Cipla and Intas and other generic producers for EU distribution.

Pfizer formerly marketed Ponstel in the USA, although some branded lines are discontinued and generics remain available.

Regulatory variability means some Asian markets sell limited OTC formulations, while the UK remains prescription-only.

In our online pharmacy, ponstan is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.

Alternative Options

Comparison Table

Which drugs are commonly chosen instead of mefenamic acid?

• Ibuprofen — strong evidence base, generally well tolerated, available OTC at lower doses.
• Naproxen — longer duration of action, useful for prolonged pain; similar GI and cardiovascular considerations.
• Paracetamol — gentler on the stomach; less effective for prostaglandin-driven cramps.

Pros And Cons

How does mefenamic acid stack up?

Mefenamic acid can be highly effective for cramps with a rapid onset for some patients but may carry higher rates of dyspepsia in observational series.

Choice should be individualised according to GI risk, cardiovascular history, renal function and patient preference.

Regulatory Status

What do regulators say about mefenamic acid?

The international nonproprietary name is mefenamic acid and the ATC code is M01AG01.

Regulatory approval varies by country but generics remain authorised across the EU and in many other jurisdictions.

In the USA the brand Ponstel was approved historically while generics remain available in some markets.

MHRA-style guidance aligns with product-information contraindications and conservative short-duration use in acute pain and dysmenorrhoea.

Pharmacovigilance updates focus on gastrointestinal, renal and rare hepatic adverse events and inform guidance on limiting duration and monitoring higher-risk patients.

Consolidated FAQ

Quick Clinical Q&A

Is ponstan available in the UK?

Generic mefenamic acid is available by prescription; specific brand availability in local pharmacies is not specified in the product data.

How quickly does mefenamic acid work?

Analgesia typically begins within 30–60 minutes after an oral dose.

Can I take it every month for period pain?

Short courses of two to three days per cycle are standard for dysmenorrhoea; seek review if pain is frequent or severe.

Is it safe with warfarin?

No — combining NSAIDs with anticoagulants increases bleeding risk and requires close monitoring or alternative analgesia.

Can children take it?

Pediatric suspensions exist in some countries, but use in children under 14 years is generally not recommended in many regions due to limited safety data.

What if a dose is missed?

Take the missed dose when remembered unless the next scheduled dose is near, and do not double doses.

Safety Q&A

When should a patient stop treatment and seek help?

Stop and seek urgent advice for black or tarry stools, severe abdominal pain, jaundice, difficulty breathing or markedly reduced urine output.

Visual Guide

Suggested Visuals For Clinicians

What should the clinic give prescribers to aid safe use?

Create a clinician flowchart that starts with indication, then checks contraindications such as NSAID allergy, peptic ulcer disease and renal/hepatic impairment.

Include a dosing and monitoring checklist noting the 500 mg loading dose and 250 mg six-hourly maintenance, with duration limits.

Patient-Facing Infographic Elements

What should a patient leaflet contain?

Key patient points: start at onset of cramps; take 500 mg initially then 250 mg every six hours; take with food to reduce stomach upset; stop after two to three days or seek advice.

Add clear red flags such as black stool, severe abdominal pain, breathlessness and reduced urine output.

Provide a comparative chart summarising onset, duration, GI risk and OTC status for mefenamic acid, ibuprofen, naproxen and paracetamol.

Storage And Transport

How should mefenamic acid be stored and handled?

Store at controlled room temperature, approximately 20–25°C, away from moisture and heat.

Keep capsules or tablets in their original container or blister to protect from humidity and to keep them out of reach of children.

Manufacturers ship under ambient conditions and no cold chain is required.

Pharmacies should rotate stock, check blister integrity and quarantine any product exposed to extremes of temperature or moisture.

Dispose of expired or returned medicines in line with NHS waste protocols.

Guidelines For Proper Use

Prescribing Checklist

What should a prescriber confirm before issuing a prescription?

Confirm the indication, ensure the patient is aged 14 years or older, review concurrent medications such as anticoagulants, ACE inhibitors, lithium or methotrexate, and assess renal and hepatic function.

Check for a history of peptic ulcer disease, NSAID allergy or recent CABG surgery.

Patient Counselling Points

What should the patient be told at the counter or clinic?

Advise taking mefenamic acid with food to reduce stomach upset.

Tell patients to avoid alcohol and additional OTC NSAIDs and to look out for red-flag symptoms like black stools or jaundice.

Recommend the lowest effective dose for the shortest possible time and document the planned duration on the prescription.

For at-risk patients, arrange baseline renal and liver function checks where appropriate and plan follow-up.

Delivery Across United Kingdom

Final Notes For Clinicians And Patients

When prescribing, follow local SmPC and MHRA-style guidance and document the rationale for short-course use.

Use the lowest effective dose and keep duration within recommended limits: up to one week for acute pain and two to three days for dysmenorrhoea.

For patients at increased gastrointestinal, renal or hepatic risk consider alternatives such as ibuprofen or paracetamol and involve specialists when needed.

Advise patients clearly about dosing, taking with food and red flags that require urgent review.

Always consult current product information for details on contraindications, interactions and monitoring requirements.